Javascript must be enabled to continue!
CD47 plays dual role in colorectal carcinoma, independently on CD 68: an immunohistochemical study
View through CrossRef
Background
Colorectal cancer (CRC) is the third most common cancer. Tumor-associated macrophages can affect tumor cell proliferation, stromal formation and dissolution, vascularization, and both pro- and anti-neoplastic inflammation. Cluster of differentiation 68 (CD68) plays a critical role in promoting phagocytosis; however, its function in tumor immunity remains unknown. CD47, a cell-surface receptor expressed by macrophages, provides a potent ‘don’t eat me‘ signal that allows tumor cells to evade immune destruction.
Purpose
Investigate immunohistochemical expression of CD68 and CD47 in CRCs and its correlation with clinicopathological features.
Results
CD68 and epithelial expression of CD47 were significantly in favor of CRC (
P
value = 0.001, <0.001, respectively) compared with adenoma specimens. Also, high epithelial CD47 was associated with the absence of gross perforation and a higher number of investigated lymph. However, low stromal CD47 was significantly correlated with less tumor metastasis and less tumor recurrence. Moreover, epithelial, and stromal CD47 expression were significantly correlated in CRC. (
P
=0.033) in CRC.
Conclusion
Both CD68 and CD47 play a role in colorectal carcinogenesis being expressed more in CRC compared with adenoma cases. However, CD47 carries good prognostic impact when expressed by tumor cells in contrary to its stromal expression suggesting dual opposing role of CD47 in CRC according to its localization. So, future target therapy against CD68 or CD47 should be cautiously administered.
Ovid Technologies (Wolters Kluwer Health)
Title: CD47 plays dual role in colorectal carcinoma, independently on CD 68: an immunohistochemical study
Description:
Background
Colorectal cancer (CRC) is the third most common cancer.
Tumor-associated macrophages can affect tumor cell proliferation, stromal formation and dissolution, vascularization, and both pro- and anti-neoplastic inflammation.
Cluster of differentiation 68 (CD68) plays a critical role in promoting phagocytosis; however, its function in tumor immunity remains unknown.
CD47, a cell-surface receptor expressed by macrophages, provides a potent ‘don’t eat me‘ signal that allows tumor cells to evade immune destruction.
Purpose
Investigate immunohistochemical expression of CD68 and CD47 in CRCs and its correlation with clinicopathological features.
Results
CD68 and epithelial expression of CD47 were significantly in favor of CRC (
P
value = 0.
001, <0.
001, respectively) compared with adenoma specimens.
Also, high epithelial CD47 was associated with the absence of gross perforation and a higher number of investigated lymph.
However, low stromal CD47 was significantly correlated with less tumor metastasis and less tumor recurrence.
Moreover, epithelial, and stromal CD47 expression were significantly correlated in CRC.
(
P
=0.
033) in CRC.
Conclusion
Both CD68 and CD47 play a role in colorectal carcinogenesis being expressed more in CRC compared with adenoma cases.
However, CD47 carries good prognostic impact when expressed by tumor cells in contrary to its stromal expression suggesting dual opposing role of CD47 in CRC according to its localization.
So, future target therapy against CD68 or CD47 should be cautiously administered.
Related Results
Complex Collision Tumors: A Systematic Review
Complex Collision Tumors: A Systematic Review
Abstract
Introduction: A collision tumor consists of two distinct neoplastic components located within the same organ, separated by stromal tissue, without histological intermixing...
Breast Carcinoma within Fibroadenoma: A Systematic Review
Breast Carcinoma within Fibroadenoma: A Systematic Review
Abstract
Introduction
Fibroadenoma is the most common benign breast lesion; however, it carries a potential risk of malignant transformation. This systematic review provides an ove...
Abstract 725: Listeria-inspired phagosome escape drives STING responses to CD47 blockade
Abstract 725: Listeria-inspired phagosome escape drives STING responses to CD47 blockade
Abstract
Purpose: Through phagocytosis, antigen-presenting cells (APCs) engulf and neutralize malignant cells. However, engulfed tumor cells are destroyed in phagol...
MO244CD47 BLOCKADE AMELIORATES AUTOIMMUNE VASCULITIS VIA THE EFFEROCYTOSIS OF NEUTROPHIL EXTRACELLULAR TRAPS*
MO244CD47 BLOCKADE AMELIORATES AUTOIMMUNE VASCULITIS VIA THE EFFEROCYTOSIS OF NEUTROPHIL EXTRACELLULAR TRAPS*
Abstract
Background and Aims
Anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is characterized by systemi...
Abstract 1645: Cell-based reporter bioassays for the development of Fc-functional and Fc-silent SIRPα/CD47 checkpoint inhibitors
Abstract 1645: Cell-based reporter bioassays for the development of Fc-functional and Fc-silent SIRPα/CD47 checkpoint inhibitors
Abstract
CD47, a membrane glycoprotein commonly overexpressed in human cancers, interacts with its cognate receptor SIRPα on myeloid cells to deliver a “don't eat me...
Transgenic expression of mutated CD47 enables CD47-CAR T cell persistence and antitumor activity in vivo 4053
Transgenic expression of mutated CD47 enables CD47-CAR T cell persistence and antitumor activity in vivo 4053
Abstract Description
CD47 is a cell surface protein that binds SIRPα on macrophages to inhibit phagocytosis. Multiple s...
Co-targeting CD47 and VEGF Elicited Potent Antitumor Effects in Gastric Cancer
Co-targeting CD47 and VEGF Elicited Potent Antitumor Effects in Gastric Cancer
Abstract
Background
CD47, serving as an intrinsic immune checkpoint, has demonstrated efficacy as an antitumor target in hematologic malignancies. Nevertheless, the clinic...
Abstract PO-009: Genetically engineered exosomes enable active pancreatic cancer targeting and evading mononuclear phagocytic system
Abstract PO-009: Genetically engineered exosomes enable active pancreatic cancer targeting and evading mononuclear phagocytic system
Abstract
Introduction: Exosomes are emerging as promising nanocarriers for genes and drugs; however, major challenges exist including the absence of active tumor tar...

